162237-91-4Relevant articles and documents
PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
-
Paragraph 0166-0167; 0171-0172, (2015/01/07)
Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
Functionalized pyrrolidines inhibit α-mannosidase activity and growth of human glioblastoma and melanoma cells
Fiaux, Hélène,Popowycz, Florence,Favre, Sylvain,Schütz, Catherine,Vogel, Pierre,Gerber-Lemaire, Sandrine,Juillerat-Jeanneret, Lucienne
, p. 4237 - 4246 (2007/10/03)
New substituted pyrrolidine-3,4-diol derivatives were prepared from D-(-)- and L-(+)-phenyl glycinol. The influence of the configuration and the substitution of the lateral side chain of these derivatives on the inhibition of 25 commercial glycosidases we
Asymmetric synthesis of protected 1,2-amino alcohols using tert-butanesulfinyl aldimines and ketimines
Tang,Volkman,Ellman
, p. 8772 - 8778 (2007/10/03)
tert-Butanesulfinyl aldimines and ketimines bearing an α-benzyloxy or α-silyloxy substituent serve as precursors in the synthesis of protected 1,2-amino alcohols in high yields and diastereoselectivities. General protocols are described for the addition of unbranched alkyl, branched alkyl, and aryl organometallic reagents to N-sulfinyl aldimines 1 and 2 and ketimines 5 and 6. Furthermore, the selective N- or O-deprotection of sulfinamide products 3, 4, 7, and 8 is described, enabling further synthetic transformations of the reaction products.